NovaBridge Biosciences (NBP) Interest Expenses (2019 - 2020)
NovaBridge Biosciences (NBP) reported Interest Expenses of -$138128.2 for Q3 2020, down 82.67% year-over-year from -$797252.5 in Q4 2019, and down 117.84% quarter-over-quarter from $774243.4 in Q4 2019.
NovaBridge Biosciences (NBP) Interest Expenses (2019 - 2020) Analysis & Trends
NovaBridge Biosciences (NBP) has 2 years of Interest Expenses data on file, last reported at -$138128.2 in Q3 2020.
- Interest Expenses for Q3 2020 came in at -$138128.2, down 82.67% year-over-year; the trailing twelve-month figure through Dec 2021 was -$138128.2 (down 121.71% YoY), and the FY2023 annual result was $102000.0, up 10300.0% from the prior year.
- Interest Expenses declined to -$138128.2 in Q3 2020 per NBP's latest filing, from $774243.4 in the prior quarter.
- Over five years, Interest Expenses peaked at $774243.4 in Q4 2019 and troughed at -$138128.2 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -5.58 Mn |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -138,128.16 |
| Sep 30, 2020 | -138,128.16 |
| Dec 31, 2019 | 774,243.36 |
| Dec 31, 2019 | 774,243.36 |
| Sep 30, 2019 | -75,614.37 |
| Sep 30, 2019 | -75,614.37 |